







The situation regarding the COVID-19 pandemic and responses to it continues to evolve 
rapidly. Regular updates are provided by the European Centre for Disease Prevention and 
Control and the World Health Organization, and in most countries national public health 
guidelines are available. The EMCDDA has created a COVID-19 resource hub that provides 
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Summary 
The Western Balkans (Albania, Bosnia and Herzegovina, Kosovo*, Montenegro, North Macedonia and 
Serbia) registered the main waves of COVID-19 infections later than most of the EU countries, but 
containment strategies were implemented at the same time and with equal force as in the rest of 
Europe. The EMCDDA initiated a series of studies using the trendspotter methodology to explore the 
impact of the pandemic and associated measures on drug services and people who use drugs in the 
Western Balkan region. The main findings are listed below. 
1. Use of alcohol, benzodiazepines, and cocaine was reported to have increased in some sub-
populations of people who use drugs. Use of benzodiazepines in combination with opioids 
was among the common risk behaviours observed during the first weeks of lockdown.    
2. A number of harms were observed among marginalised and injecting drug users, who in some 
cases lacked resources to satisfy basic needs. Mental health problems were reported among 
both recreational and problem drug users.  
3. The provision of drug treatment was reduced during the first weeks of the pandemic, affecting 
mainly new admissions and services provided face to face. 
4. The number of people entering treatment declined between March and May 2020 in almost all 
countries in the Western Balkan region.  
5. Opioid substitution treatment (OST) centres and harm reduction services mainly remained 
operational, although under a restricted regime. 
6. The main adaptations to the new situation included use of telemedicine and a relaxation of 
OST distribution schemes.  
7. Personal protection measures became standard in all treatment and harm reduction facilities, 
and protective equipment was distributed to clients whenever possible.  
 
The crisis highlighted the fragile position of some service providers and the reliance of harm reduction 
services on the support of international donors.  
Introduction 
Across Europe, drug services and people who use drugs faced a number of particular challenges and 
risks as a result of the COVID-19 pandemic (EMCDDA 2020b, 2020c). In order to better understand 
the impact of COVID-19 on the drug situation in the Western Balkans, the EMCDDA initiated a series 
of mini-trendspotter studies focusing on drug services and help seeking behaviours, on patterns of 
drug use and drug-related harms, and on drug markets. This briefing presents results of the first two 
studies focusing on drug use and harms and on drug services, which were carried out between June 
and August 2020. The objective of this exercise is to describe the main effects of COVID-19-related 
restrictions on the drug using population and on the provision and demand for drug services, and their 
 
* This designation is without prejudice to positions on status, and is in line with UNSCR 1244/1999 and the ICJ 
Opinion on the Kosovo Declaration of Independence. 
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gradual adaptation to the changing situation, in the EU candidate and potential candidate countries 
from the Western Balkan region (Albania, Bosnia and Herzegovina, Kosovo, Montenegro, North 
Macedonia and Serbia).  
Trendspotter methodology 
The trendspotter methodology is a structured rapid assessment approach triangulating information 
from a range of qualitative and quantitative sources, including expert opinion (EMCDDA, 2018). The 
method has been adapted to the virtual environment due to the need to investigate the impact of 
COVID-19 on drug use and drug services in the EU Member States (EMCDDA, 2020a).  
 
The analysis presented in this briefing is based on the following data sources: 
§ a review of the international literature and online resources (including webinars and online 
conferences); 
§ available epidemiological data from the region; 
§ online surveys disseminated among national drug observatories and EMCDDA IPA 7 national 
correspondents, and among experts and professionals in the treatment and harm reduction 
field; 
§ three online facilitated groups comprising 19 practitioners, advocacy groups and professional 
networks representatives.  
 
FIGURE 1 




It should be noted that, in general, the availability of data on drug use and drug use patterns is low in 
the Western Balkan region; a situation made worse by the responses to COVID-19. Existing 
monitoring systems on health-related aspects of the drug situation are typically under the responsibility 
of national institutes of public health or other departments of ministries of health. Staff working on drug 
monitoring were often reallocated to management of COVID-19 in their country, and monitoring work 
was suspended in some instances. In the absence of data on drug use patterns and harms, related 
analysis presented in this briefing relies mainly on observations of professionals working directly with 
people who use drugs and, to a lesser extent, on data from treatment.  
Planning 
 
- Virtual team meetings 
- Adapt TS method 
- Identify data sources 
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- Online surveys 
- Facilitated groups 












National responses over time 
In the early days of the COVID-19 pandemic, the Western Balkan region registered relatively small 
numbers of positive cases. The governments reacted swiftly and during March imposed a number of 
restrictive measures, including stay-at-home orders, closures of non-essential services and limitations 
on internal and cross-border travel (See Table 1).  
 
TABLE 1 
A timetable of national responses to the COVID-19 pandemic 





Date for lifting of 
restrictions 
Albania 9 March 2020 9 March 2020 4 May 2020 
Bosnia and 
Herzegovina 
5 March 2020 16 March 2020 24 April 2020 
Kosovo 13 March 2020 15 March 2020 4 May 2020 
Montenegro 17 March 2020 Not declared 2 June 2020 
North 
Macedonia 
26 February 2020 18 March 2020 28 May 2020 
Serbia 6 March 2020 15 March 2020 28 May 2020 
 
The early and radical mitigating measures were deemed effective in containing the virus (Demirgüç-
Kunt et al., 2020) and between the end of April and early June the restrictions began to ease. In the 
summer, the numbers of registered cases of COVID-19 increased sharply across the region and new 
waves of selectively imposed measures followed (see Figure 2).  
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FIGURE 2  
Development of new infections in the Western Balkans, new cases per day by country  
 
Source: JHU Dong et al. 2020. 
Factors affecting levels and patterns of drug use 
Shutting down national economies restricted the movement of people and goods, and also affected 
the drug markets in the Western Balkan region. Travel restrictions and stay-at-home orders 
substantially reduced the time people spent outdoors, which also narrowed the opportunities to obtain 
drugs. Bars, clubs, and other nightlife venues where recreational drug use often occurs were closed in 
most of the region during the first weeks of the pandemic, and Montenegro and Serbia reported that 
this reduced nightlife use of stimulants. Marginalised groups, typically opioid users who relied on 
begging and other means of generating income on the street, in many cases lost access to their usual 
resources and drugs became less affordable. These circumstances, however, changed as soon as the 
national restrictions were lifted. For instance, practitioners from Serbia reported that after 12 May, 
when the country reopened its economy, major festivals were attended by thousands of people, and 
private parties took place outdoors across Belgrade.  
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Participants in surveys and facilitated groups identified changes in prices and availability of drugs 
during the lockdown that are likely to have affected levels of use. However, these accounts were not 
always consistent across the region and varied for different substances. Kosovo, Montenegro, North 
Macedonia and Serbia reported a rise in the of price of cannabis while, at the same time, along with 
Bosnia and Herzegovina, a stable or decreasing price of cocaine. The price of heroin remained stable 
according to participants from Bosnia and Herzegovina and Serbia, although clients of harm reduction 
programmes in Montenegro and Serbia reported low quality, and in Bosnia and Herzegovina reduced 
availability of the drug. Increased availability of diverted buprenorphine on the street market was 
reported in Bosnia and Herzegovina and Montenegro, and some practitioners linked this to alterations 
in the prescription regimes (see the section ‘Challenges and adaptations of drug services’).  
New substances and patterns of use 
Information on patterns of drug use is available mainly for high risk drug users, and for those in 
contact with drug services, as the majority of the study participants were harm reduction and drug 
treatment practitioners. Moreover, interventions aimed at recreational drug use or nightlife settings are 
rare in the region, except for Serbia. Little is also known about the impact of the pandemic on 
cannabis use.  
 
Among the most commonly reported changes across the region was increased consumption of alcohol 
and psychoactive medicines, either alone, together, or in combination with other drugs – a 
phenomenon also observed elsewhere in Europe (EMCDDA, 2020d). In Kosovo and Montenegro, new 
treatment demands related to alcohol use problems were reported among both current users of illicit 
drugs and those who had stopped using illicit drugs. A variety of explanations were provided for 
increases in use of benzodiazepines and other psychoactive pharmaceuticals (often obtained from 
peers and relatives or found at home). These included coping with lockdown-related anxiety, replacing 
drugs that were not accessible, managing withdrawal symptoms, and potentiating the effect of lower 
doses of drugs. An increase of simultaneous use of multiple drugs among clients was reported 
specifically by practitioners from Bosnia and Herzegovina, Kosovo, Montenegro, and North 
Macedonia. 
 
The presence of cocaine on the drug market and its use by different sub-populations of drug users 
became more visible across all countries in the Western Balkan region during the first months of the 
pandemic. In Albania, cocaine was the most common reason to seek treatment in the Mother Theresa 
Hospital before the lockdown. In Kosovo, cocaine use rose among treatment entrants and among 
users of party drugs such as MDMA, amphetamines, and GHB after the economy was shut down, and 
similarly use of cocaine was said to be more common in North Macedonia following the imposition of a 
curfew. Increased injecting of cocaine, or of cocaine in combination with heroin, was reported from 
Montenegro. In Serbia, cocaine was reported to have taken over from amphetamines among 
recreational drug users despite its higher price. 
 7 
      
Alterations of usual routes of administration were also sporadically reported, such as snorting of 
crushed benzodiazepines and switching to (or more frequent) injecting in North Macedonia, injecting 
of drugs that were usually used by other means in Montenegro, injecting of buprenorphine diverted 
from prescriptions in Bosnia and Herzegovina and Montenegro, or injecting home-made drug mixtures 
containing benzodiazepines in Serbia. 
 
Case study 1: Survey among clients of a drop-in centre in Montenegro 
In March, soon after the confinement measures were announced in Montenegro, the NGO Juventas, 
that operates a needle-syringe programme in Podgorica, started collecting data from clients about 
their experiences during the pandemic and about the impact of COVID-19 on the perceived availability 
and purity of drugs. The study was initiated with the objective of better tailoring services to the 
changing needs of their clients during the time of crisis. The programme serves about 500 users of 
mainly opioids, sometimes in combination with stimulants. The information here is based on answers 
from about 10 % of the clients. 
 
Respondents reported that overall availability of commonly used illicit drugs did not decrease during 
the lockdown, but they sometimes became less accessible or less affordable. Clients also reported 
that the purity of drugs, especially of heroin, was much lower during the lockdown. The price of 
cannabis and heroin increased in the same period; while the cost of cocaine dropped, although this 
tendency was already observed before COVID-19. The price of illegally sold buprenorphine remained 
stable, but the substance was reported to become slightly more available, possibly in relation to an 
increase of take-home dosages. Buprenorphine tablets, as well as heroin and cocaine, are used 
mainly by injection in this sub-group. 
 
The lockdown measures resulted in dramatic changes in quality of life for many clients of the 
programme, whose usual sources of income were no longer available. In response, the centre started 
offering food packages, and increased the provision of personal hygiene and laundry services. More 
clients also required psychosocial support, as they could not access their social networks. An 
increasing trend of combining alcohol with illicit drugs and psychoactive medicines also put clients at 
higher risk of overdose. The staff of the drop-in centre observed an overall deterioration in the health 
of their clients, in some cases with fatal consequences.  
 
Risky behaviours, harms and needs 
In terms of harms among people who use drugs, marginalised drug users and low-income individuals 
appeared to be affected most by the lockdown. Seasonal and food industry work, often taking place in 
the grey economy, were discontinued and an increased number of clients fell into poverty. Basic 
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needs such as food, personal hygiene, and laundry became extremely difficult to satisfy for many. 
Stigma reportedly complicated access for this group to general healthcare.   
 
Emergency room data and statistics on drug-related deaths are not available from the region, but 
practitioners from Albania, Kosovo and North Macedonia reported overdose deaths among their 
clients during the lockdown and associated these deaths with using combinations of substances 
(typically benzodiazepines and opioids) or large amounts of consumed drugs. In Montenegro, two 
clients were reported to die from non-COVID-19 lung infection, starvation and general sepsis. Cases 
of drug-related violence were reported from Albania and Kosovo, and experts from across the region 
expected a rise of drug-related criminality in the coming months. 
 
Mental health issues have been observed among both recreational and more problematic drug users. 
In Montenegro, the needle and syringe programme reported more clients seeking support for 
loneliness, anxiety and depression. In Serbia, recreational drug users were described as manifesting 
more depressive symptoms, difficulties in coping with daily routines without their weekend drug use 
and previously unnoticed symptoms of addiction.  
 
The potential of contracting COVID-19 was mentioned by many, although by the end of June, none of 
the participants in facilitated groups and surveys reported COVID-19-positive clients. This may be also 
explained by the relative isolation of people who use drugs from people who travel outside of the 
country. Among the risky practices mentioned by experts in this context were sharing joints and lack of 
protective measures in the nightlife settings after the re-opening of the economy.  
Availability of drug services 
National drug observatories and health service practitioners across the region reported that some drug 
services with direct contact with clients, primarily outpatient treatment and psychosocial support, were 
discontinued or only provided remotely. Drug treatment in general health care settings (general 
practitioners and hospitals) was not provided during the lockdown in North Macedonia and Serbia and 
was reduced in Albania. In Serbia, patients of facilities that were repurposed for COVID-19 cases were 
referred to other centres, although this has been listed among the main challenges by the National 
Drug Observatory. Therapeutic communities and in-patient treatment centres, including some 






Case study 2: Shortage of methadone in Albania 
In Albania, no methadone was available for a period of 3 weeks in July following a delay in deliveries 
due to restrictions on commercial transport. At the beginning of April, it became apparent that the 
stock would not last until the next delivery expected in June 2020, and Aksion Plus, the only provider 
of methadone in the country, started lowering the daily doses to all 850 of their clients, including those 
receiving OST in prison. Due to COVID-19, the shipment only arrived on 21 July, five weeks after the 
first centres ran out of methadone.  
 
As a consequence, some clients were reported to have switched to buprenorphine, and some 
received emergency treatment for withdrawal symptoms at the toxicological department of the Mother 
Theresa University Hospital. A number of clients turned to injecting street heroin. Aksion Plus reported 
worries of increased aggression within families, rise of criminal behaviour and an elevated risk of 
transmission of HIV and hepatitis. Some clients of the programme were admitted to prison during the 
shortage. Methadone provision resumed on 22 July 2020 in all 9 centres and the majority of clients 
returned to treatment.  
 
Opioid substitution treatment (OST) centres showed flexibility in adapting to the new situation across 
the region. The only reported exception was a methadone programme in Albania that was closed for 
several weeks due to a nationwide shortage of the drug (see Case study 2). Most of the OST centres 
in the remaining countries in the region continued dispensing medication during the lockdown and 
beyond, although it was not possible for new clients to initiate treatment in some centres (for instance 
in Bosnia and Herzegovina and North Macedonia). A number of OST providers changed their 
prescription and distribution schemes in response to travel restrictions and to reduce face to face 
contact with clients.  
 
The impact of the pandemic and subsequent response on harm reduction services was mixed. Drop-in 
centres in Bosnia and Herzegovina and in Serbia were closed by government order as a safety 
precaution, and both drop-in and outreach work were temporarily discontinued in Kosovo. Wherever 
possible, the services continued to be provided under restricted regimes and in the context of strict 
safety precautions, or remotely. In Montenegro, the drop-in centre in Podgorica reduced the working 
hours but remained operational during the pandemic and reported more clients than normal. In North 
Macedonia, contact with clients had to be pre-arranged by phone. In the absence of a drop-in centre, 
the provision of clean injection material continued outdoors in Bosnia and Herzegovina and 
Montenegro. Some programmes reported that interventions deemed high-risk in terms of COVID-19 
transmission (such as testing for infectious diseases) were not offered to clients during the first weeks 
of the pandemic. In this context, it should be noted that even under normal circumstances the 
provision of harm reduction services is low in most parts of the Western Balkan region (for instance, 
there is no needle and syringe programme in Belgrade, the capital of Serbia) and the existing 
programmes struggle with financial uncertainty. Yet, the operational harm reduction providers from 
across the region managed to function under the restrictions and registered and responded to a 
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number of new needs, especially among marginalised users (including provision of protective 
equipment and covering basic needs, such as food and basic hygiene).  
 
After the main body of restrictions was lifted across the region, some centres re-opened although the 
restricted regimes and strict safety measures remained in place. In early July, there was still no return 
to normal reported by any of the participants of the facilitated groups.  
Help seeking and treatment demand 
A short-term decline in the number of clients entering treatment during COVID-19 restrictions was 
reported in Albania, Bosnia and Herzegovina and Serbia. In Albania, the total number of clients 
entering treatment in the Mother Theresa Hospital dropped from 47 in January and 45 in February, to 
16 in March, 13 in April and 11 in May, after some of the treatment facilities were reserved for COVID-
19 cases (see Figure 3). In Serbia, the number of clients starting OST treatment dropped from 
between 21 and 25 per month in the first quarter of 2020 to 3 in both April and in May; in June the 
requests returned to 21.  
 
FIGURE 3 
Number of people starting treatment at the Clinical Toxicology Service, University Hospital 
‘Mother Theresa’, Tirana, Albania  
  
Source: MTUH 2020. 
 
In Bosnia and Herzegovina, where data were available for one agency, the Federation of Bosnia and 
Herzegovina, a similar pattern was observed in both OST and hospital treatment requests. The lowest 
numbers were reported for April and May and no patients started treatment with buprenorphine during 
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Data from Kosovo show a different picture, with the highest number starting treatment in April, after a 
gradual increase of numbers observed from the beginning of the year (see Figure 4). The extent to 
which the peak was a result of reduced access to drugs during lockdown is not known.  
 
FIGURE 4 
Number of people starting treatment in three cities in Kosovo  
 
Source: Labyrinth 2020. 
 
A number of factors may have contributed to the declines in Albania, Bosnia and Herzegovina and 
Serbia including the following: reduced availability of treatment options, suspension of admissions of 
new clients, temporary closure of centres, limited or unavailable public transport and restricted 
movement of persons.  
 
The overall numbers may, however, hide differences between sub-populations of clients. For instance, 
in Montenegro the decrease of treatment demand was noted in particular among heroin users and 
people entering OST. In North Macedonia, OST centres registered an influx of patients released from 
prisons, returnees from abroad, and locals who could not access or afford to buy street heroin, while 
regional centres saw fewer clients due to the absence of public transport. In Kosovo, more cocaine 
users and more people from the Roma minority sought treatment during the first months of the 
pandemic. In Albania, older drug users that had never been previously treated appeared in treatment 
soon after the main restrictions were lifted.     
Challenges and adaptations of drug services  
After lockdown, the most immediate challenge for treatment and harm reduction providers was to 
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Telemedicine was a viable option for most of the psychosocial and counselling services where face to 
face interventions were no longer possible. Treatment professionals from all countries reported a 
move to consultations by phone or video. In addition, a help-line for clients of harm reduction services 
was initiated in Montenegro, and a universal national help-line also served people who use drugs. 
Some harm reduction services maintained contact with their clients via multiple channels, including 
social media and mobile communication apps, which were available practically non-stop, in order to 
respond to emergencies.  
 
However, remote service provision was not without problems. It was reported from North Macedonia, 
that some clients, especially those with dual diagnoses or tendencies to psychosis, did not respond 
well to counselling over the phone. For some marginalised groups of people who use drugs, access to 
the internet during lockdown was difficult or impossible. It was also reported that in North Macedonia, 
Roma populations in more remote areas of the country were less likely to use prevention services 
offered via telephone.    
 
Where the services required direct contact with clients or a collaboration of multiple staff members, 
measures preventing the transmission of the SARS-CoV-2 virus had to be implemented, including 
social distancing and personal protection. Study participants from across the region reported that 
protective equipment (masks, gloves, sanitisers) was extremely expensive or inaccessible at the 
beginning of the pandemic, though the situation gradually resolved after a few weeks. Only 
Montenegro did not report a rise in prices, although there were shortages of the protective materials. 
In March, the Office for Combatting Drugs of the Government of the Republic of Serbia provided 
protective material to non-governmental organisations. In late April, harm reduction centres from North 
Macedonia and Serbia reported that they had enough protective material for their staff but not for the 
clients due to overall underfinancing (DPNSEE, 2020).  
 
Harm reduction and treatment professionals across the region provided additional services in 
response to the pandemic. Marginalised clients had to be informed about the ongoing pandemic and 
educated in protective measures, and this became a new routine service provided to clients. 
Participants in facilitated groups reported that most of their clientele manifested solidarity with each 
other and with the staff working with them and followed the safety guidelines. One OST centre in North 
Macedonia installed a video-surveillance system in order to monitor and enforce safe behaviours. 
Nevertheless, physical distancing was challenging for those who were acutely intoxicated. Maintaining 
basic hygiene became an issue for homeless drug users, and one of the drop-in centres in 
Montenegro responded to by increasing provision of personal hygiene and laundry services. The 
same centre also provided food packages to about 50 families experiencing financial problems. In 
some countries, new client groups entered services, including users of new types of drugs or 
members of the Roma minority. Increased use of alcohol and benzodiazepines among clients of harm 
reduction services in Bosnia and Herzegovina resulted in acute intoxications impacting psychomotor 
abilities, which required adaptation of existing interventions. Diagnostic testing for SARS-CoV-2 was 
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offered by at least one centre in the region that also reported purchasing medicines to relieve 
symptoms of potential COVID-19 cases.  
 
During the summer months of 2020, a harm reduction programme in Montenegro reported a notable 
reduction in COVID-19 awareness among clients, requiring a reinforcement of the rules.  
 
In response to restrictions on individual travel, lack of public transport, or quarantine and self-isolation 
of clients, new delivery methods were introduced for services that could not be provided remotely, 
especially clean injecting material and OST medications. Needle and syringe programmes in at least 
two countries encouraged peer distribution of the material. Home delivery of OST medication was also 
reported, with the assistance of either police or charity organisations; some OST centres also provided 
certificates to clients that would allow them to travel (see Case study 3). In North Macedonia, 
decentralisation of buprenorphine treatment allowed access to buprenorphine in regional OST centres. 
Relaxation of strict prescribing rules has been reported across the region. Typically, the daily on-site 
application was replaced by up to two-weeks take-home dosage for both buprenorphine and 
methadone for all, not just stabilised, clients. In Montenegro, the extended supply of take-home 
buprenorphine was provided subject to a negative urine drug test. Most of these changes were 
implemented on the level of individual organisations (for instance in Montenegro, only some centres 
started providing take-home OST) and were considered temporary. In Montenegro, the OST 
programme returned to the normal regime after the national restrictions were lifted, but after two 
months and rising numbers of new COVID-19 infections in the country the weekly distribution was 
restarted. The relaxation did not affect the criteria to enter treatment, as was the case in some EU 
Member States in response to the crisis (EMCDDA, 2020b). On the contrary, if there was a change in 
admission policy it was a restriction on new entries. 
 
Case study 3: Relaxing opioid substitution treatment rules in Montenegro 
Opioid Substitution Centre Kotor, Montenegro, operating since 2010, provides methadone or 
buprenorphine therapy to about 300 clients from a region of nearly 100 000 inhabitants. The two 
substances are distributed under different schemes. While methadone may be given to stabilised 
clients on a weekly basis, buprenorphine can only be distributed in daily doses according to existing 
national guidelines. The national response to the COVID-19 during the first weeks of the pandemic 
represented a barrier to access to treatment for all OST clients regardless of the prescribed drug. The 
initial measures included 28 days of complete lockdown, with severe restrictions on the movement of 
persons and the suspension of public transport. The Kotor OST centre responded quickly and started 
providing medical certificates to their clients allowing them to travel for treatment and changed the 
distribution scheme for buprenorphine to a weekly dosing. As a result, no significant drop-out from 
treatment was observed and regular urine screening showed no substantial increase in the use of illicit 
drugs among the clients. An increase of use of benzodiazepines was observed, possibly as a way of 
coping with anxiety.  
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Staff shortages due to lack of childcare or transportation, quarantine, or reallocation of medical staff to 
COVID-19-related work and financial instability presented additional challenges. For instance, 
Margina, the only harm-reduction provider in the Federation of Bosnia and Herzegovina, ran out of 
funds during the lockdown and continued providing outreach services only with the help of unpaid 
staff; while Aksion Plus in Albania lowered salaries due to lack of resources. Worries about the future 
of drug services in terms of sustainability, especially about harm reduction provided by civil society, 
were voiced by focus group participants from across the region.   
Guidelines and international cooperation 
Shortly after governments across Europe started responding to the pandemic, it became apparent that 
people who use drugs may face additional risks, and the modus operandi of services would have to be 
adapted. Recommendations issued at national level usually described general safety and protective 
measures. With the exception of Serbia, where the Ministry of Health instructed the OST centres to 
provide take-home dosage, there was no information about national guidelines specifically focusing on 
drug services in the Western Balkan region. Organisations providing drug treatment and harm 
reduction often developed their own protocols or translated and adapted guidelines produced by 
international organisations and networks. Among documents mentioned by participants in our 
facilitated groups and surveys were those prepared by the EMCDDA (EMCDDA, 2020a), UNAIDS, 
UNODC, and by the International Network of People who Use Drugs (INPUD). 
 
The role of international networks and organisations has been important throughout the course of the 
pandemic, although practically mainly civil society benefited from their activities. During the lockdown 
weeks, organisations such as the Drug Policy Network South East Europe (DPNSEE), Correlation 
network, INPUD, and Eurasian Harm Reduction Association (EHRA) organised virtual meetings and 
webinars in order to share experiences and best practice, and to help identify potential donors. These 
activities continued to a lesser extent after the restrictions were lifted and more information became 
available about the virus. 
 
The support of international donors is fundamental for the provision of harm-reduction services in the 
region, and during the first months of the pandemic their role became even more visible. For instance, 
Open Society Foundation (OSF) financed food provision for marginalised populations, including 




Using the trendspotter methodology, this report shows that the virus containment measures 
implemented by national governments in the Western Balkans impacted on the lives of people who 
use drugs and disrupted normal provision of drug services during the first weeks of the pandemic.  
 
Drug use in nightlife settings ceased with the closure of the venues, which also reduced the 
opportunity to obtain drugs for many recreational drug users. Use of alcohol and benzodiazepines 
became more common among different user sub-populations, and the presence of cocaine on drug 
markets in the Western Balkan region became more apparent. Marginalised and injecting drug users 
were significantly affected by the lockdowns, as many of them lost income and shelter and were 
stripped of basic resources.   
 
Availability and accessibility of both drug treatment and harm reduction services was substantially 
reduced across the region during the first weeks of the pandemic. New treatment admissions were, in 
general, limited to emergency cases. In order to remain operational, providers had to adapt to new 
circumstances: many services became available online or via telephone, a number of protective 
measures were implemented, and innovative strategies were applied to maintain treatment and to 
reach clients who became harder to access. Efforts to adapt to new needs of marginalised drug users 
were reported by harm reduction services from across the region.  
 
The availability of harm reduction services, especially needle and syringe programmes, was already 
limited in the region, and civil society organisations struggled before the crisis. The vulnerability of 
some care agencies, mainly harm reduction services, became even more apparent during the 
pandemic. Some services remained available and some of the changes were possible thanks to 
support of international organisations, networks and donors. In June and July, when the economies 
resumed, the drug services were still slowly finding their way to pre-pandemic levels of service 
provision. The concern remains that COVID-19 and responses to it may result in further reduction of 
resources and reinforce the reliance on international funding. 
 
The longer-term impact of the pandemic on drug treatment systems in the Western Balkans is difficult 
to predict and will require further monitoring. Some of the adaptations, such as the relaxation of OST 
provision schemes, are devised as temporary. Other innovations, such as telemedicine, may be seen 
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